Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
Stopped Due to inability to meet accrual goals within the funding period.
Conditions
Interventions
- DRUG: Dupilumab
- DRUG: Placebo
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]